IP Group plc (LSE: IPO) (“IP Group” or “the Group”), the developer of intellectual property-based businesses, is pleased to note that portfolio company Genomics plc (“Genomics”) and Oxford University’s Wellcome Trust Centre for Human Genetics (“WTCHG”) confirmed they have sequenced and analysed multiple human genomes using hand-held technology from portfolio company Oxford Nanopore Technologies Ltd (“Nanopore”). Using Nanopore’s portable MinION sequencer, the WTCHG and Genomics team sequenced a standard human reference sample, NA12878. In addition, in collaboration with the NIHR Oxford Biomedical Research Centre, they sequenced the DNA from a clinical patient. Alan Aubrey, Chief Executive of IP Group, said: “It’s exciting to see two of our portfolio companies collaborating in this world first. Nanopore has made significant scientific and commercial progress this year, is starting to gain real traction in industry and is being recognised at the highest levels. Genomics, meanwhile, is emerging as the leading genome analytics company. We remain excited about the prospects of both businesses.”